Search Results - "Luboshits, G."

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells by Bashari, O., Redko, B., Cohen, A., Luboshits, G., Gellerman, G., Firer, M.A.

    Published in Cancer letters (01-11-2017)
    “…Metastatic castration-resistant prostate cancer (mCRPC) remains essentially incurable. Targeted Drug Delivery (TDD) systems may overcome the limitations of…”
    Get full text
    Journal Article
  2. 2

    A novel delta opioid receptor specific peptide reduces craving in an animal model of cocaine seeking by Itzhak-Israeli, Pnina Shirel, Yael, Hevroni, Matsree, Erez, Pe'er-Nissan, Hilla, Lancman, Shira Ofer, R, Barnea, G, Luboshits, Motiei, Menachem, Betzer, Oshra, Gispan, Iris, Popovtzer, Rachela, Anker, Yaakov, MA, Firer, G, Yadid

    Published in Addiction neuroscience (01-09-2024)
    “…Substance use disorder, and particularly cocaine use disorder, is a complex disease that affects societal, economic, and psychological factors. Endogenous…”
    Get full text
    Journal Article
  3. 3

    New somatostatin-drug conjugates for effective targeting pancreatic cancer by Ragozin, E., Hesin, A., Bazylevich, A., Tuchinsky, H., Bovina, A., Shekhter Zahavi, T., Oron-Herman, M., Kostenich, G., Firer, M.A., Rubinek, T., Wolf, I., Luboshits, G., Sherman, M.Y., Gellerman, G.

    Published in Bioorganic & medicinal chemistry (30-07-2018)
    “…[Display omitted] •New cyclic peptide-drug conjugates for effective targeting pancreatic cancer were discovered.•These conjugates comprising cyclic peptides…”
    Get full text
    Journal Article
  4. 4

    Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families by Yado, S., Luboshits, G., Hazan, O., Or, R., Firer, M. A.

    Published in Journal for immunotherapy of cancer (14-11-2019)
    “…BackgroundDespite chemo-induction therapy and autologous stem cell transplantation (ASCT), the vast majority of patients with Multiple Myeloma (MM) relapse…”
    Get full text
    Journal Article
  5. 5

    Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma by Gilad, Y., Tuchinsky, H., Ben-David, G., Minnes, R., Gancz, A., Senderowitz, H., Luboshits, G., Firer, M.A., Gellerman, G.

    Published in European journal of medicinal chemistry (29-09-2017)
    “…The resistance of cancer cells to chemotherapeutic agents, whether through intrinsic mechanisms or developed resistance, motivates the search for new…”
    Get full text
    Journal Article
  6. 6
  7. 7

    MS-KIF18A, a kinesin, is associated with estrogen receptor by Luboshits, G., Benayahu, D.

    Published in Journal of cellular biochemistry (15-02-2007)
    “…The study of MS‐KIF18A kinesin protein is focused on its cellular distribution and association with a cargo protein. Indirect immunofluorescence (IF) analyzed…”
    Get full text
    Journal Article
  8. 8

    MS-KIF18A, new kinesin; structure and cellular expression by Luboshits, G., Benayahu, D.

    Published in Gene (23-05-2005)
    “…The present study describes the cloning and molecular analysis of a new gene, MS-KIF18A, a member of the kinesin family. MS-KIF18A was cloned from a marrow…”
    Get full text
    Journal Article
  9. 9

    Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes by Mor, Adi, Luboshits, Galia, Planer, David, Keren, Gad, George, Jacob

    Published in European heart journal (01-11-2006)
    “…Considerable evidence supports the role of innate and adaptive immunity in the progression and destabilization of the atheromatous plaque. Naturally occurring…”
    Get full text
    Journal Article
  10. 10

    Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific V[beta] T cell families by Yado, S, Luboshits, G, Hazan, O, Or, R, Firer, M. A

    Published in Journal for immunotherapy of cancer (14-11-2019)
    “…Background Despite chemo-induction therapy and autologous stem cell transplantation (ASCT), the vast majority of patients with Multiple Myeloma (MM) relapse…”
    Get full text
    Journal Article
  11. 11

    The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity by AZENSHTEIN, Elina, LUBOSHITS, Galia, SHINA, Sima, NEUMARK, Eran, SHAHBAZIAN, David, WEIL, Miguel, WIGLER, Nely, KEYDAR, Iafa, BEN-BARUCH, Adit

    Published in Cancer research (Chicago, Ill.) (15-02-2002)
    “…Breast cancer progression may be affected by various cellular components expressed by the tumor cells and/or by microenvironmental factors. Many studies report…”
    Get full text
    Journal Article
  12. 12

    Elevated expression of the CC chemokine Regulated on activation, normal T Cell Expressed and Secreted (RANTES) in advanced breast carcinoma by LUBOSHITS, G, SHINA, S, KAPLAN, O, ENGELBERG, S, NASS, D, LIFSHITZ-MERCER, B, CHAITCHIK, S, KEYDAR, I, BEN-BARUCH, A

    Published in Cancer research (Chicago, Ill.) (15-09-1999)
    “…Breast carcinoma is the most common malignant disease among women and the second most lethal one. In search for a better understanding of the role of cellular…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease by Wigler, Nely, Shina, Sima, Kaplan, Ofer, Luboshits, Galia, Chaitchik, Samario, Keydar, Iafa, Ben-Baruch, Adit

    Published in The Israel Medical Association journal (01-11-2002)
    “…High incidence and intensity of RANTES (CC chemokine) expression were noted in advanced breast carcinoma. To present two cases of breast carcinoma patients in…”
    Get full text
    Journal Article
  15. 15